Welcome to our dedicated page for Zimmer Biomet SEC filings (Ticker: ZBH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Zimmer Biomet Holdings, Inc. (NYSE: ZBH) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Zimmer Biomet is a global medical technology company focused on musculoskeletal health and orthopedic implants, and its filings offer detailed insight into its operations, capital structure, risk factors and governance.
Through this page, you can review annual reports on Form 10-K and quarterly reports on Form 10-Q, which discuss Zimmer Biomet’s product categories such as knees, hips, sports medicine, extremities, trauma, craniomaxillofacial and thoracic (S.E.T.), and technology and data, bone cement and surgical. These reports typically include segment and geographic sales information, descriptions of the company’s digital and robotic technologies, and management’s discussion and analysis.
You will also find current reports on Form 8-K covering material events, including quarterly earnings releases, new debt issuances, revolving credit agreements, acquisitions such as the merger with Monogram Technologies Inc., and other significant corporate developments. Filings describing the company’s notes and bonds, including series listed on the New York Stock Exchange, provide detail on interest rates, maturities, covenants and redemption features.
Stock Titan enhances these documents with AI-powered summaries that explain key points in clear language, helping users navigate complex topics like non-GAAP financial measures, leverage covenants and transaction structures. The platform also surfaces insider and executive-related filings, such as those reporting departures or appointments of certain officers, so users can track governance changes. With real-time updates from EDGAR and AI-generated highlights, this page is a focused resource for analyzing Zimmer Biomet’s SEC reporting history and ongoing regulatory disclosures.
Zimmer Biomet Holdings senior vice president and chief legal officer Chad F. Phipps reported an equity award tied to past performance. He acquired 4,692 restricted stock units as of February 19, 2026, at a stated price of $0.00 per unit. These RSUs were earned under a performance-based grant covering the 2023–2025 period and are scheduled to vest on March 6, 2026. Each RSU represents the right to receive one share of Zimmer Biomet common stock.
Zimmer Biomet Holdings reported that Group President, Asia Pacific, Yi Sang acquired 7,050 restricted stock units (RSUs) at a price of $0.00 per unit. These RSUs were earned from performance-based awards granted in March and September 2023 for the 2023–2025 performance period.
Based on actual performance determined on February 19, 2026, Yi Sang earned 5,298 RSUs from the March 2023 grant and 1,752 RSUs from the September 2023 grant. Each RSU represents a contingent right to receive one share of Zimmer Biomet common stock and the 7,050 RSUs will vest on March 6, 2026.
ZIMMER BIOMET HOLDINGS, INC. Chairman, President and CEO Ivan Tornos reported an acquisition of 24,436 restricted stock units (RSUs) tied to prior performance-based awards. Each RSU represents a contingent right to receive one share of Zimmer Biomet common stock at no purchase price.
The RSUs relate to performance-based grants awarded in March and September 2023 for a 2023–2025 performance period. Based on actual performance determined on February 19, 2026, he earned 12,184 RSUs from the March grant and 12,252 RSUs from the September grant, which together will vest on March 6, 2026 if conditions are satisfied.
Zimmer Biomet Holdings, Inc. files its annual report describing a global orthopedic and musculoskeletal business built around knees, hips, S.E.T. (sports medicine, extremities, trauma, CMFT) and a growing digital and robotic ZBEdge platform. The company sells mainly through consignment, which represented about 85% of 2025 net sales, with no single customer over 2%.
Operations are organized into Americas, EMEA and Asia Pacific, with the U.S. dominating Americas and Japan leading Asia Pacific. As of February 10, 2026, there were 195,652,004 common shares outstanding, and non‑affiliate share value was about $18.0 billion as of June 30, 2025.
Zimmer Biomet highlights extensive R&D with roughly 2,000 employees, heavy regulation from FDA, EU MDR and other regimes, and growing scrutiny on data privacy, cybersecurity and AI. The report details risks around competition, pricing pressure, restructuring, product portfolio rationalization, supply chain, ERP implementation issues, cyber attacks, high leverage of about $7.5 billion of debt, tax changes and global macro uncertainty.
Harris Associates has disclosed a sizable stake in Zimmer Biomet Holdings, Inc. common stock. Through Harris Associates L.P. and Harris Associates, Inc., the firm reports beneficial ownership of 12,264,703 shares, representing 6.2% of Zimmer Biomet’s common stock.
Harris reports sole voting power over 11,892,571 shares and sole dispositive power over 12,264,703 shares, with no shared voting or dispositive power. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Zimmer Biomet.
Yi Sang reported open-market sale transactions in a Form 4 filing for ZBH. The filing lists transactions totaling 1,000 shares at a weighted average price of $96.49 per share. Following the reported transactions, holdings were 17,670 shares.
A shareholder of ZBH has filed a notice of proposed sale of restricted securities under Rule 144. The filing covers 1,000 shares of common stock, with an aggregate market value of 96,490.00, to be sold through Fidelity Brokerage Services LLC on the NYSE around February 12, 2026.
The shares were originally acquired from the issuer on March 6, 2024 through restricted stock vesting as part of compensation, rather than a cash purchase. By signing the notice, the seller represents that they are not aware of any material adverse, non-public information about the issuer’s current or prospective operations.
Zimmer Biomet reported solid 2025 growth with mixed earnings trends and new capital return plans. Fourth quarter net sales were $2.244 billion, up 10.9% reported and 5.4% on an organic constant currency basis. Full-year net sales reached $8.232 billion, an increase of 7.2% reported and 3.9% on an organic constant currency basis.
GAAP diluted EPS fell to $0.70 in the quarter, down 41.7%, and to $3.55 for the year, down 19.9%, largely reflecting higher costs and charges. Adjusted diluted EPS was $2.42 for the quarter, up 4.8%, and $8.20 for the year, up 2.5%. The company generated $1.697 billion in operating cash flow and $1.172 billion of free cash flow in 2025.
The Board authorized a new $1.5 billion stock repurchase program with no expiration date, after completing $250 million of buybacks in the fourth quarter. For 2026, Zimmer Biomet guides to reported revenue growth of 2.5%–4.5%, organic constant currency growth of 1.0%–3.0%, and adjusted diluted EPS of $8.30–$8.45, as it shifts toward a more direct and specialized U.S. sales model.
Zimmer Biomet Holdings, Inc. reported that Mark Bezjak, who was identified as a named executive officer in the company’s 2025 proxy statement, has informed the company he will resign his employment. His resignation, including all officer positions with Zimmer Biomet and its affiliates, will be effective January 16, 2026 so he can pursue another business opportunity.
The company previously disclosed that Mr. Bezjak ceased to be an executive officer of Zimmer Biomet as of July 1, 2025, so this filing formalizes his departure from remaining roles with the organization.
Zimmer Biomet Holdings, Inc. director Louis Shapiro reported a routine equity-related transaction involving deferred compensation. On 12/31/2025, he acquired 152.22 phantom stock units tied to Zimmer Biomet common stock under the company’s Deferred Compensation Plan for Non-Employee Directors. Each unit is convertible into one share of common stock, and the units are scheduled to be settled in company shares within sixty days after he ceases serving as a director. Following this transaction, he beneficially owned 2,500.354 phantom stock units, which includes 5.625 units previously accrued on 10/31/2025 through the plan’s dividend reinvestment provision.